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ABSTRACT 
 
Objective: Impaired endothelial function was demonstrated in HIV-infected persons 
on protease-inhibitor (PI)-containing antiretroviral therapy, probably due to altered 
lipid metabolism. Atazanavir is a PI causing less atherogenic lipoprotein changes. 
We studied whether endothelial function improves after switching from other PI to 
atazanavir. 
 
Design: Randomized, observer-blind, treatment-controlled trial. 
 
Setting: Three university-based outpatient clinics. 
 
Patients: 39 HIV-infected persons with suppressed viral replication on PI-containing 
regimens and fasting LDL-cholesterol >3mmol/L. 
 
Intervention: Patients were randomized either to continue the current PI or change 
to unboosted atazanavir.  
 
Main outcome measures: Endpoints at week 24 were endothelial function 
assessed by flow-mediated vasodilation (FMD) of the brachial artery, lipid profiles, 
high sensitive C-reactive protein, malondyaldehyde, total antioxidative capacity and 
oxidized LDL.   
 
Results: Baseline characteristics and mean FMD values of the two treatment 
groups were comparable (3.9±1.8% on atazanavir vs. 4.0±1.5% in controls). After 
24 weeks’ treatment, FMD decreased to 3.3±1.4% and 3.4±1.7%, respectively (all 
p=n.s.). Total cholesterol improved in both groups (p=<0.0001 and p=0.01, 
respectively) but changes were more pronounced on atazanavir (p=0.05, changes 
between groups). HDL and triglyceride levels improved on atazanavir (p=0.03 and 
p=0.003, respectively) but not in the control group. Serum inflammatory and 
oxidative stress parameters did not change; oxidized LDL improved significantly in 
the atazanavir group. 
 
Conclusions: The switch from another PI to atazanavir among treatment 
experienced patients did not result in improvement of endothelial function despite 
significantly improved serum lipids. Not only atherogenic lipid profiles but also direct 
effects of reverse transcriptase inhibitor plus PI-containing combination on the 
endothelium may affect vascular function. 
ClinicalTrials.gov Identifier:  NCT00447070 
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INTRODUCTION 
 
Morbidity and mortality of HIV-infected persons with access to combination 
antiretroviral therapy (cART) have dramatically improved. However, there is a major 
concern that cART is associated with premature manifestation of coronary artery 
disease (CAD).1,2 Protease inhibitors (PI) are among the key components of cART 
and several studies propose a direct association between the use of PI and an 
increased risk of CAD,3-6 although this relation has been questioned. Combination 
ART, particularly PI-containing regimens, is associated with hyperlipidemia, 
hyperglycemia, insulin resistance, central obesity, and other metabolic factors 
known to promote vascular disease and premature CAD.7 
 
Endothelial function, a powerful surrogate marker of early atherosclerosis,8 has 
been found to be reduced in treated HIV-infected persons,9 even in young 
children,10 when compared with uninfected individuals. Recent reports have 
demonstrated impaired endothelial function especially in HIV-infected persons on 
PI, probably due to an altered lipid metabolism.10,11 In contrast, improvement of 
endothelial function was measured in HIV-infected persons on PI-containing cART 
who started lipid lowering therapy with statins although this could also be attributed 
to their pleiotropic effect.12 In comparison with other PI, atazanavir is a PI causing 
less atherogenic lipoprotein changes.13 Whether this feature of atazanavir leads to 
preserved endothelial function and subsequently to a lower incidence of 
cardiovascular complications, however, is unclear at present because long-term 
observations are missing. 
 
Hence, this randomized controlled multi-centre study aimed to prospectively 
evaluate endothelial function, serum lipid profiles and serum inflammatory and 
oxidative stress surrogate parameters over a period of 24 weeks in persons on PI-
containing cART and suppressed viral replication who either continued the current 
PI or switched to atazanavir-containing combination therapy. 
 
 
METHODS 
 
Patient characteristics, inclusion and exclusion criteria 
Eligible were male and female HIV-infected persons between 18 and 65 years old 
on stable combination antiretroviral treatment with 2 nucleoside reverse 
transcription inhibitors (NRTI) and one PI (other than atazanavir) for at least 12 
weeks, with two consecutive viral load assessments below 50 copies/mL within 60 
days prior to study entry, CD4 lymphocyte counts above 100 cells/µL, a treatment 
history and results of prior resistance testing allowing replacement of the current PI 
by unboosted atazanavir, and LDL cholesterol above 3.0 mmol/L.   
 
Exclusion criteria were known coronary artery disease, hypertension, peripheral 
artery disease, cerebrovascular disease, and diabetes mellitus. Furthermore, 
patients with serious illness requiring systemic treatment and/or hospitalization 
within 14 days prior to study entry, current drug or alcohol addiction or patients 
participating in other studies were excluded, as well as patients with previous 
virologic failure on PI containing regimens and previously documented protease 
resistance mutations. The use of non-nucleoside reverse transcriptase inhibitors, 
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testosterone or anabolic steroids, systemic glucocorticoids, long-acting inhaled 
steroids or other immunomodulators at study entry or during the study led to 
exclusion, as did the use of any lipid-lowering drugs within 4 weeks prior to study 
entry. Pregnancy was ruled out by pregnancy test. 
 
Study protocol 
A total of 41 patients were enrolled in this observer-blinded, randomized controlled 
multi-centre study using a parallel group design between 4. August 2004 and 24. 
October 2005. During the screening period, two assessments of endothelial function 
by flow mediated dilation (FMD) were performed (at least one week apart), and the 
mean of the 2 assessments was the baseline value. Because FMD is dependent on 
many factors including gender, smoking, alcohol consumption, degree and duration 
of hypertension or dyslipidemia, the participants were stratified by the FMD-operator 
after the two baseline measurements into two groups: (1) persons with mean FMD 
below 2.0%, and (2) persons with mean FMD equal or above 2.0%. The allocation 
schedule for the two treatment arms, including the two different strata with randomly 
permuted block sizes of 2 and 4, was generated in advance with the program 
RandList Version 1.0.0.107 (DatInf GmbH Tübingen, Germany), and two separate 
series of sealed envelopes were prepared for the two FMD strata.  
 
Participants were then randomized by the study nurse of the HIV outpatient clinic to 
receive either 400 mg open-label unboosted atazanavir daily, instead of the current 
PI, or to continue the currently used PI. Both groups maintained the two reverse 
transcriptase inhibitors unaltered. Clinical visits were performed after 4, 12 and 24 
weeks. At weeks 12 and 24 measurement of flow-mediated vasodilation was 
repeated. Patient’s compliance to treatment and procedures were assessed at each 
visit. Returned study medications were counted to determine whether they were 
consistent with the number prescribed.  
  
Screening and study visits were performed at specialized HIV outpatient clinics of 3 
tertiary care University Hospitals in Switzerland (Zurich, Bern and Lausanne). The 
local ethics committees of these University Hospitals approved the study protocol 
and all procedures were in accordance with institutional guidelines and the 
Declaration of Helsinki. Written informed consent was obtained from all study 
participants. 
 
Assessment of endothelial function 
Assessments were performed in dedicated cardiovascular ultrasound laboratories of 
the University hospitals, maintaining a standardized protocol. Physicians of these 
centers and the Flow-mediated dilation (FMD) operator remained blinded 
throughout the study and data analysis. FMD examinations were performed in a 
temperature controlled, quiet room in the morning. Patients were examined in the 
fasting state and were asked to quit smoking at least 2 hours before examination 
and to refrain from coffee, tea, fruits and chocolate for at least 24 hours. Flow-
mediated dilation (FMD) and glycerol-trinitrate (GTN)-induced vasodilation (0.4 mg 
sublingual, Nitrolingual Spray, Pohl-Boskamp, Germany) of the brachial artery were 
assessed by a high-resolution ultrasound vessel wall tracking device with a 10-MHz 
linear array transducer according to guidelines.14,15
 Flow-mediated reactive 
hyperemia reflects endogenous nitric oxide (NO) formation, resulting in 
endothelium-dependent vasodilation, while GTN acts as an exogenous NO donor 
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directly on vascular smooth muscle cells inducing endothelium-independent 
vasodilation. FMD of the brachial artery was induced by release of a wrist cuff 
inflated to 220mmHg pressure for 5 minutes. After release, we recorded the arterial 
diameter every 15 seconds for 2 minutes. After GTN application, we recorded the 
diameter every 30 seconds for 6 minutes. 
 
Serum inflammation and oxidative stress parameters 
Malondialdehyde was derivatized and measured on a HPLC system with a 
fluorescence detector with a limit of detection of 0.01 µmol/l and a coefficient of 
variation of 3% (Chromsystems, Munich, Germany). Highly sensitive C-reactive 
protein (hsCRP) was measured on an Immulite 2500 immunoanalyzer using 
commercial assays with a limit of detection of 0.1 mg/l and a coefficient of variation 
of 6% (DPC, Los Angeles, CA, USA). The oxidized LDL was measured by ELISA 
with a limit of detection of 1 mU/l and a coefficient of variation of 8% (Mercodia, 
Uppsala, Sweden) and the total antioxidative capacity (TAOC) was measured using 
Trolox as a standard with a limit of detection of 0.04 mmol/l and a coefficient of 
variation of 3.4% (Cayman Chemicals, Ann Arbor, MI, USA). 
 
Statistical analysis 
The authors had full access to the data and take responsibility for its integrity. 
Statisticians remained blinded throughout the predefined primary data analysis. For 
comparison of baseline characteristics between treatment groups, t-tests or Fisher's 
exact tests were used. Primary endpoints were changes of endothelial function at 
the end of the 24-week study period comparing the two treatment arms using t-tests 
and individual changes using paired t-tests. The sample size of 38 participants was 
calculated to detect a 20% difference in the change of FMD (power of 80%; 
α=0.05). The following secondary endpoints were analyzed: changes of lipid 
profiles, serum inflammatory and oxidative stress parameters. Repeating the 
analyses with non-parametric methods yielded comparable results and therefore we 
only report results from two-sided parametric tests. We used Stata 9.2 (Stata Corp, 
College Station, Tx). 
 
 
 
RESULTS 
 
Study participants 
Two of 41 enrolled patients dropped out before randomization. We therefore report 
results on 39 participants (20 in the atazanavir arm and 19 in the continued PI arm). 
Baseline characteristics including PI treatment at enrollment are presented in Table 
1. Except for the baseline serum triglycerides, which were significantly higher in the 
atazanavir group, both treatment arms were equally balanced. Mean duration of 
HIV-seropositivity as well as duration of antiretroviral and PI therapy tended to be 
slightly longer in the atazanavir group (n.s.). HIV surrogate markers did not differ 
between the two treatment arms. 
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Table 1. Patient characteristics 
 
 
Atazanavir 
(n=20) 
Continued 
protease 
inhibitor 
(n=19) 
p 
Men, no. (%) 15 (75 %) 15 (79%) 1.0 
Mean age [years] (± SD) 46 (±7.5) 47 (±12.5) 0.80 
Current smokers, n (%) 9 (45%) 7 (37%) 0.61 
Mean body-mass-index [kg/m2] (± SD)  23 (±3.0) 24 (±2.3) 0.37 
Mean (± SD) duration of HIV-seropositivity [years]  10 (±5.5) 7.6 (±4.7) 0.14 
Mean (± SD) duration of antiretroviral therapy 
[years]  
7.7 (±3.7) 5.7 (±3.1) 0.07 
Protease inhibitors at time of randomization*   0.426 
   Lopinavir/Ritonavir 5 (25.0) 3 (15.8)  
   Nelfinavir 13 (65.0) 16 (84.2)  
   Ritonavir (therapeutic dose) 1 (5.0) 0 (0)  
   Indinavir/Ritonavir 1 (5.0) 0 (0)  
Clinical HIV stage CDC C, no. (%) 5 (25 %) 5 (26 %) 0.45 
Mean (± SD) systolic blood pressure [mmHg]  125 (±13) 125 (±17) 0.96 
Mean (± SD) diastolic blood pressure [mmHg]  77 (±8.8) 77 (±9.0) 0.91 
Mean (± SD) pulse (1/min) 75 (±7.4) 74 (±9.5) 0.64 
No. (%) with HIV-1 RNA <50 copies/mL 20 (100%) 19 (100%) 1.0 
Mean (± SD) CD4 count [cells/µL] 539 (±250) 520 (±324) 0.84 
Mean (± SD) total cholesterol [mmol/L] 6.5 (±0.95) 6.5 (±1.1) 0.78 
Mean (± SD) LDL [mmol/L] 4.0 (±0.96) 4.2 (±0.9) 0.52 
Mean (± SD) HDL [mmol/L] 1.2 (±0.4) 1.2 (±0.3) 0.85 
Mean (± SD) triglycerides [mmol/L] 3.2 (±1.6) 2.3 (±1.0) 0.04 
Mean (± SD) fasting glucose [mmol/L] 5.1 (±0.6) 5.0 (±0.5) 0.57 
Mean (± SD) insulin [mIU/L)] 16.5 (±18) 10.5 (±8.4) 0.19 
 
Footnote of table 1 
* The reverse transcriptase inhibitor backbone in the atazanavir and continued protease inhibitor 
groups, respectively, were statistically not different: zidovudine plus lamivudine, 14 and 13 patients; 
abacavir plus lamivudine, 0 and 4 patients; stavudine plus lamivudine, 2 and 1 patients; didanosine 
plus lamivudine, 1 and 1 patient;  lamivudine plus  tenovovir, 1 and 0 patients; zidovudine plus 
tenofovir, 1 and 0 patients; didanosine plus stavudine, 1 and 0 patients, respectively. 
_____ 
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Course of treatment 
Of the 39 patients, 38 (97%) completed the 24 week trial. One patient in the 
atazanavir arm stopped the assigned treatment after 2 months. There were no 
serious adverse events or new AIDS-defining illnesses throughout the study. 
However, 4 (21%) patients in the continued PI arm experienced virological failure 
versus none in the atazanavir arm.  
 
Endothelial function 
Baseline brachial artery diameter matched well at baseline and did not significantly 
change during the 24-week study period (from 4.60±0.78 mm to 4.56±0.76 mm, 
p=0.90, in the atazanavir group, and from 4.68±0.61 mm to 4.74±0.61 mm, p=0.78, 
in the continued PI group). Flow-mediated vasodilation did not change after the 
switch to atazanavir or during continued PI therapy (from 4.0±1.5% to 3.4±1.7%, 
p=0.40, and from 3.9±1.8 to 3.3±1.4%, p=0.37, respectively; Figure 1). Atazanavir 
and continued PI arms combined showed FMD changes from 3.9±1.6% to 
3.4±1.5% (p=0.22) during the study period. Also, nitroglycerine-mediated 
vasodilation and blood flow did not change during the study (all p=n.s.). 
 
Serum lipid levels and liver enzymes 
During the study period, serum lipid levels improved both in the atazanavir and 
continued PI arm (Table 2, Figure 2). In the atazanavir group, however, the 
improvement was more pronounced. Total cholesterol, LDL cholesterol, HDL 
cholesterol and triglycerides were significantly improved after 24 weeks of 
atazanavir treatment, whereas triglycerides and HDL did not change in the 
continued PI arm. Liver enzymes were slightly but statistically significantly higher 
after the 24 weeks of atazanavir treatment compared with the baseline values, 
whereas the liver enzymes remained stable on continued PI therapy. 
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Table 2. Comparison of the two treatment groups at baseline and at 24 weeks 
 
Atazanavir arm Continued protease inhibitor arm  
Baseline 
(n=20) 
W24 
(n=19)§ 
p*  Baseline 
(n=19) 
W24 
(n=19) 
p*  
p†  p‡ 
SBP (mmHg) 125 (±13) 121 (±13) 0.08 126 (±17) 120 (±17) 0.18 0.95 0.84 
DBP (mmHg) 77 (±9) 77 (±9) 0.94 77 (±9) 73 (±7) 0.04 0.19 0.15 
Pulse (1/min) 75 (±7) 72 (±7) 0.19 74 (±10) 69 (±6) 0.02 0.21 0.67 
No. (%) with HIV-1 RNA 
<50 copies/mL 
20 (100%) 19 (100%) 0.15 19 (100%) 15 (78.9%) 0.32 0.31 0.30 
HIV-1 RNA || (log10 
copies/mL) 
0.03 (±0.15) 0.17 (±0.4) 0.15 0.32 (±0.6) 0.58 (±1.5) 0.32 0.24 0.30 
CD4 lymphocyte count 
(cells/µL) 
539 (±250) 543 (±247) 0.14 520 (±324) 489 (±382) 0.61 0.62 0.38 
ALAT (U/L) 31.7 (±14.6) 40.4 (±17.4) 0.002 28.4 (±14.7) 30.4 (±12.3) 0.70 0.05 0.02 
ASAT (U/L) 31.5 (±12.1) 37.4 (±20.1) 0.02 29.2 (±12.5) 29.0 (±10.5) 0.95 0.12 0.09 
Total cholesterol 
(mmol/L) 
6.5 (±0.95) 5.5 (±1.2) <0.001 6.5 (±1.1) 5.8 (±0.8) 0.007 0.29 0.048 
LDL (mmol/L) 4.0 (±0.96) 3.3 (±1.2) <0.001 4.2 (±0.9) 3.8 (±0.7) 0.02 0.13 0.13 
HDL (mmol/L) 1.2 (±0.4) 1.3 (±0.4) 0.03 1.2 (±0.3) 1.2 (±0.28) 0.77 0.29 0.07 
Triglycerides (mmol/L) 3.2 (±1.6) 2.0 (±1.6) 0.003 2.3 (±1.0) 2.0 (±1.0) 0.13 0.97 0.03 
Fasting glucose 
(mmol/L) 
5.1 (±0.6) 5.2 (±0.5) 0.28 5.0 (±0.45) 5.0 (±0.54) 0.78 0.17 0.36 
Insulin (mIU/L) 16.5 (±18) 12.3 (±13.6) 0.35 10.5 (±8.4) 7.9 (±5.0) 0.14 0.20 0.69 
hsCRP (mg/L) 2.0 (±1.8) 2.5 (±3.3) 0.58 1.5 (±1.3) 1.8 (±1.5) 0.45 0.43 0.87 
oxLDL (U/L) 68.9 (±15.6) 55.1 (±14.6) <0.001 77.7 (±16.1) 70.2 (±14.2) 0.048 0.003 0.16 
MDA (µmol/L) 0.12 (±0.04) 0.12 (±0.02) 0.85 0.13 (±0.05) 0.12 (±0.05) 0.47 0.93 0.62 
TAOC (mM) 2.7 (±0.65) 2.7 (±0.67) 0.82 2.6 (±0.64) 2.7 (±0.75) 0.12 0.76 0.18 
 
Footnotes of table 2: 
Data are presented as mean ± SD. SBP denotes systolic blood pressure, DBP=diastolic blood 
pressure,  ALAT=Alanine-Amino Transferase, ASAT=Aspartat-Aminotransferase, LDL=low density 
lipoprotein, HDL=high density lipoprotein, hsCRP=high sensitivity C-reactive protein, 
oxLDL=oxidised LDL, MDA=malondialdehyde, TAOC=total antioxidative capacity 
*
 p values within groups from a paired=matched t-test 
†
 p-values between groups from two-sided t-tests: intergroup groups at week 24; 
‡ p-values between groups from two-sided t-tests: intragroup (changes from baseline to week 24) 
§
 no data at week 24 for one patient ||
 values below limit of detection are coded as 1 copy/mL (i.e. log10(1)=0) 
_____ 
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Serum inflammation and oxidative stress parameters 
The inflammation parameter high sensitivity C-reactive protein (hsCRP) as well as 
the oxidative stress parameters malondyaldehyde (MDA) and total antioxidative 
capacity (TAOC) did not change significantly during the course of the study (Table 
2). Oxidized LDL changed significantly in the atazanavir group; however, the 
changes were in parallel with LDL, therefore no conclusion concerning oxidative 
stress can be reached. 
 
 
 
DISCUSSION 
 
In this randomized, controlled study we found that a switch from another protease 
inhibitor to an unboosted atazanavir-containing combination antiretroviral therapy 
did not result in an improvement of endothelial function after 24 weeks despite a 
significantly improved lipid profile. 
 
This result is intriguing as dyslipidemia is associated with endothelial dysfunction 
and, vice versa, improvement of blood lipids ameliorates endothelial vascular 
function,16,17 as previously demonstrated in HIV-infected persons on PI who 
received pravastatin treatment.12 Therefore, an improvement of endothelial function 
after atazanavir therapy was expected. However, because serum lipids not only 
improved in the atazanavir arm, as expected, but also - less profound - in the 
control group (although the addition of lipid lowering drugs was not allowed during 
the 24 week study period), the course of lipid levels might have influenced the 
results of endothelial function in favour of the control group. In previous studies, 
treatment with PI was associated with impairment in serum lipid profiles as well as 
impaired endothelial function,18 however, such effect has been seen after initiating 
the drug. In contrast, our patients already were on stable PI treatment for months or 
years before they were enrolled in this study. The improvement of serum lipids 
during the study could be explained by the adherence of patients and physicians to 
treatment guidelines which recommend changes of life-style and behaviour in order 
to reduce cardiovascular risks. The fact that at the end of the study systolic blood 
pressure tended to be lower in both groups and diastolic blood pressure and heart 
rate were significantly lower in the control group after 24 weeks as compared to 
baseline is suggestive for such a healthier life-style. However, lower blood pressure 
is also associated with an ameliorated endothelial function, an effect not seen in our 
study. 
 
The lacking improvement of vascular function after replacement of another PI with 
atazanavir may also be explained by a direct effect of the NRTI plus PI-containing 
antiretroviral combination treatment on the endothelium. Based on in vitro 
experiments as well as clinical investigations in HIV-infected patients and in persons 
not infected with HIV, toxic effects and other direct effects on the endothelium have 
been postulated, including a decrease of endothelium-dependent vasorelaxation, 
inhibition of the nitric oxide synthase system, increase of oxidative stress, and 
activation of mitogen-activated protein kinases.11,18-20 Direct effects on the 
endothelium, as for example increased oxidative stress or an inflammatory 
response of the vessel wall, were mainly associated with PI. Nevertheless, results 
of animal models indicate that also reverse transcriptase inhibitors can directly 
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affect the vascular endothelium.21 As a consequence, not only PI inhibitors but 
rather the combination therapy with reverse transcriptase inhibitors plus PI could 
counterbalance the expected beneficial effect of an improved lipid profile associated 
with, e.g., atazanavir, or other single drugs that do not influence lipid profiles. The 
participants of the trial presented here were indeed already on long-term 
antiretroviral therapy before enrolment, namely for a mean of 6.7 years on any 
antiretroviral drugs, and a mean of 5.6 years on combination drug regimens, which 
may have affected vascular endothelial function. And, although patients were 
randomized, the mean duration of previous antiretoviral therapy among the 
atazanavir group was 2 years longer than in the continuing PI group. 
 
The results of flow-mediated dilation in our study participants indicated endothelial 
dysfunction as compared to in healthy persons not infected with HIV, but, we do not 
have any indices of increased inflammation or oxidative stress at baseline or after 
24 weeks of treatment. The surrogate serum biomarkers of inflammation and 
oxidative stress, including hsCRP, malondyaldehyde, oxizeded LDL, or total 
antioxidative capacity were not significantly influenced by atazanavir or continued 
PI, although earlier reports suggested increasing oxidative stress due to PI 
therapy.22 
 
Antiretroviral drugs can cause drug-induced liver injury.23,24 In our study, liver 
enzymes increased mildly but significantly after switching to atazanavir treatment, 
possibly indicating some toxic effect of this drug, which might also affect the 
endothelium. A recent study in patients with diabetes mellitus type 2 showed an 
inverse correlation between liver enzymes and flow-mediated dilation.25 Moreover, 
toxic effects to the liver might lead to an inflammatory response, not only affecting 
liver enzymes but also leading to complex inflammatory responses possibly 
affecting endothelial function. However, we did not observe hsCRP serum 
concentrations to increase after atazanavir treatment. 
 
The strengths of our study include the randomization of persons with suppressed 
viral replication, and the stratification based on baseline flow-mediated dilation, 
which may control for the various cardiovascular risk factors in the different 
treatment arms. Possible limitations include the sample size and the probably too 
short duration of the study. Despite the fact that randomization balanced the two 
groups quite well, HIV-infected persons have heterogeneous co-morbidities, co-
medication, different lifestyles including heterogeneous cardiovascular risk 
behaviour and a high prevalence of smoking, all factors known to influence 
endothelial function. Therefore, such confounding factors may have influenced our 
study endpoints. Furthermore, although unlikely, the higher baseline triglyceride 
levels might have contributed to a false low endothelial function in the atazanavir 
group, thus confounding our results. 
 
In conclusion, we found marked endothelial dysfunction - a powerful surrogate for 
atherosclerosis - among our study participants who were on antiretroviral therapy 
for a mean of 6.7 years. We now demonstrate that switching PI therapy to 
atazanavir, a new PI not negatively altering lipid-profiles and therefore considered to 
be less atherogenic, has no beneficial impact on the vascular endothelium, thus 
probably not solving the important problem of vascular dysfunction in these patients. 
However, the clearly demonstrated positive effect on the lipid-profile may, in the 
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long term, still be beneficial in respect to cardiovascular morbidity and mortality. 
Therefore, further long-term observations are needed to determine whether the 
incidence of clinical endpoints of cardiovascular diseases will decrease among 
persons on atazanavir-containing antiretroviral regimens. Changing current 
(effective) PI therapy to atazanavir merely in the hope for reduced cardiovascular 
risk may not be appropriate at the present time as definitive data is lacking. It is, 
however, important to take other preventive measures and to strictly treat 
cardiovascular risk factors in this patient group. 
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Figure legends: 
 
Figure 1.  
Vascular function. Panel A: Endothelial function measurement. Flow mediated 
dilation (FMD) did not change after atazanavir as well as after continued protease 
inhibitor-containing therapy (from 4.0±1.5% to 3.4±1.7%, p=0.4 and from 3.9±1.8 to 
3.3±1.4%, p=0.37, respectively). Panel B: Similarly, endothelial-independent, 
glycerol-trinitrate (GTN) [nitroglycerine] mediated vasodilation did not change during 
the study (from 11.7±5.1% to 10.8±4.6%, p=0.64 and from 11.7±5.3 to 10.6±3.8, 
p=0.45) 
 
Figure 2.  
Serum lipids. Panel A: Total Cholesterol (tot Chol) decreased from 6.5±0.95 to 
5.5±1.2 mmol/l, p<0.0001, in the atazanavir group, and from 6.5±1.1 to 5.8±0.8 
mmol/l, p=0.007, in the control group. The effect of atazanavir on total cholesterol 
was significantly more pronounced than the control PI (p=0.48). Panel B: Low 
density lipoprotein (LDL) decreased from 4.0±1.0 to 3.3±1.2 mmol/l, p<0.001, in the 
atazanavir group and from 4.2±0.9 to 3.8±0.7 mmol/l, p=0.02, in the control group. 
Panel C: High density lipoprotein (HDL) increased from 1.2±0.4 to 1.3±0.4 mmol/l, 
p=0.03, in the atazanavir group, whereas HDL remained unchanged in the control 
group (1.2±0.3 and 1.2±0.3 mmol/l). Panel D: Triglycerides were significantly 
lowered in the atazanavir group (from 3.2±1.6 to 2.0±1.6 mmol/l, p= 0.003), 
however remained stable in the control group (from 2.3±1.0 to 2.0±1.0 mmol/l). 
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